In:
ChemMedChem, Wiley, Vol. 17, No. 10 ( 2022-05-18)
Abstract:
A focused drug repurposing approach is described where an FDA‐approved drug is rationally selected for biological testing based on structural similarities to a fragment compound found to bind a target protein by an NMR screen. The approach is demonstrated by first screening a curated fragment library using 19 F NMR to discover a quality binder to ACE2, the human receptor required for entry and infection by the SARS‐CoV‐2 virus. Based on this binder, a highly related scaffold was derived and used as a “smart scaffold” or template in a computer‐aided finger‐print search of a library of FDA‐approved or marketed drugs. The most interesting structural match involved the drug vortioxetine which was then experimentally shown by NMR spectroscopy to bind directly to human ACE2. Also, an ELISA assay showed that the drug inhibits the interaction of human ACE2 to the SARS‐CoV‐2 receptor‐binding‐domain (RBD). Moreover, our cell‐culture infectivity assay confirmed that vortioxetine is active against SARS‐CoV‐2 and inhibits viral replication. Thus, the use of “smart scaffolds” based on binders from fragment screens may have general utility for identifying candidates of FDA‐approved or marketed drugs as a rapid repurposing strategy. Similar approaches can be envisioned for other fields involving small‐molecule chemical applications.
Type of Medium:
Online Resource
ISSN:
1860-7179
,
1860-7187
DOI:
10.1002/cmdc.202200092
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2209649-8
SSG:
15,3
